The use of reaction time distributions to study attention in male rats: the effects of atomoxetine and guanfacine
- 107 Downloads
Norepinephrine (NE) is involved in the control of sustained attention. Studies of sustained attention in humans include measures of reaction time (RT) and RT variability (RTV). The present study tested the role of NE using components of the RT distribution in rats in a manner thought to be similar to human studies of RTV.
This study tested the effects of increased synaptic NE (atomoxetine (ATX)) and α-2 receptor binding (guanfacine) on attentional lapses in rats.
Male Sprague-Dawley rats (n = 20) were trained and tested in a two-choice RT task (2CRTT). Atomoxetine dose (saline, 0.1, 0.5, 1.0 mg/kg, i.p.), guanfacine dose (saline, 0.01, 0.1, 0.3 mg/kg, i.p.), and distractors were manipulated in three experiments. RT was divided into initiation time (IT) and movement time (MT). Analyses of distribution mode (peak) and deviation from the mode (skew) were then performed.
ATX and guanfacine had no effect on IT mode, reduced IT devmode, and increased MT mode. When distractors were introduced, ATX again improved devmode, but a lack of interaction between ATX and distractor indicated that ATX did not prevent distractor-induced impairments.
IT devmode is a measure of distribution skew thought to reflect lapses of attention. The effects of ATX on IT devmode suggest that increased synaptic NE reduces attentional lapses. These findings are consistent with human reports of reduced RTV after ATX administration. The same pattern of results with guanfacine suggests that the effects of increased NE are due in part to binding at α-2 noradrenergic receptors.
KeywordsNorepinephrine α-2 noradrenergic receptors Atomoxetine Guanfacine Rat Lapses of attention Distribution skew Reaction time variability ADHD Distractors
The department of Psychology at the University of Mississippi provided funding for this project.
Compliance with ethical standards
All procedures using animals were approved by the University of Mississippi Institutional Animal Care and Use Committee.
Conflict of interest
The authors declare that they have no conflicts of interest.
- Barkley RA (2006) Attention-deficit hyperactivity disorder: a handbook for diagnosis and treatment, 3rd edn. Guilford Press, New YorkGoogle Scholar
- Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH, Morin SM, Gehlert DR, Perry KW (2002) Atomoxetine increases extracellular level of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27:699–711PubMedCrossRefGoogle Scholar
- Caballero-Puntiverio M, Lerdrup LS, Grupe M, Larsen CW, Dietz AG, Andreasen JT (2019) Effect of ADHD medication in male C57BL/6J mice performing the rodent continuous performance test. Psychopharmacology:1–13Google Scholar
- Fernando ABP, Economidou D, Theobald DE, Zou M, Newman AH, Spoelder M, Caprioli D, Moreno M, Hipólito L, Aspinall AT, Robbins TW, Dalley JW (2012) Modulation of high impulsivity and attentional performance in rats by selective direct and indirect dopaminergic and noradrenergic receptor agonists. Psychopharmacology 219:341–352PubMedCrossRefGoogle Scholar
- Kratochvil CJ, Heiligenstein JH, Dittmann R, Spencer TJ, Biederman J, Wernicke J, Newcorn JH, Casat C, Milton D, Michelson D (2002) Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry 41:776–784PubMedCrossRefGoogle Scholar
- Kratz O, Studer P, Baack J, Malcherek S, Erbe K, Moll GH, Heinrich H (2012) Differential effects of methylphenidate and atomoxetine on attentional processes in children with ADHD: an event-related potential study using the Attention Network Test. Prog Neuro-Psychopharmacol Biol Psychiatry 37:81–89CrossRefGoogle Scholar
- Lin HY, Gau SSF (2016) Atomoxetine treatment strengthens an anti-correlated relationship between functional brain networks in medication-naïve adults with attention-deficit hyperactivity disorder: a randomized double-blind placebo-controlled clinical trial. Int J Neuropsychopharmacol 19:1–15CrossRefGoogle Scholar
- Michelson D, Allen AJ, Busner J, Casat C, Dunn D, Kratochvil C, Newcorn J, Sallee FR, Sangal RB, Saylor K, West S, Kelsey D, Wernicke J, Trapp NJ, Harder D (2002) Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 159:1896–1901PubMedCrossRefGoogle Scholar
- Ni HC, Hwang Gu SL, Lin HY, Lin YJ, Yang LK, Huang HC, Gau SSF (2016) Atomoxetine could improve intra-individual variability in drug-naïve adults with attention-deficit/hyperactivity disorder comparably with methylphenidate: a head-to-head randomized clinical trial. J Psychopharmacol (Oxf) 30:459–467CrossRefGoogle Scholar
- Richards J, Gancarz A, Hawk, Jr. L (2011) Animal models of behavioral processes that underlie the occurrence of impulsive behaviors in humans. In: Inhibitory control and drug abuse prevention: from research to translation. Springer Science & Business Media, pp 13–41Google Scholar
- Scahill L, Chappell P, Kim Y, Schultz RT, Katsovich L, Shepherd E, Arnsten AFT, Cohen DJ, Leckman JF (2001) A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry 158:1067–1074PubMedCrossRefGoogle Scholar
- Tomlinson A, Grayson B, Marsh S, Harte MK, Barnes SA, Marshall KM, Neill JC (2014) Pay attention to impulsivity: modelling low attentive and high impulsive subtypes of adult ADHD in the 5-choice continuous performance task (5C-CPT) in female rats. Eur Neuropsychopharmacol 24:1371–1380PubMedCrossRefGoogle Scholar
- Tsutsui-Kimura I, Ohmura Y, Izumi T, Yamaguchi T, Yoshida T, Yoshioka M (2009) The effects of serotionin and/or noradrenaline reuptake inhibitors on impulsive-like action assessed by the three-choice serial reaction time task: a simple and valid model of impulsive action using rats. Behav Pharmacol 20:474–483PubMedCrossRefGoogle Scholar
- Wang M, Ramos BP, Paspalas CD, Shu Y, Simen A, Duque A, Vijayraghavan S, Brennan A, Dudley A, Nou E, Mazer JA, McCormick DA, Arnsten AFT (2007) α2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex. Cell 129:397–410PubMedCrossRefGoogle Scholar
- Wehmeier PM, Schacht A, Ulberstad F, Lehmann M, Schneider-Fresenius C, Lehmkuhl G, Dittmann RW, Banaschewski T (2012) Does atomoxetine improve executive function, inhibitory control, and hyperactivity?: results from a placebo-controlled trial using quantitative measurement technology. J Clin Psychopharmacol 32:653–660PubMedCrossRefGoogle Scholar
- Wehmeier PM, Schacht A, Wolff C, Otto WR, Dittmann RW, Banaschewski T (2011) Neuropsychological outcomes across the day in children with attention-deficit/hyperactivity disorder treated with atomoxetine: results from a placebo-controlled study using a computer-based continuous performance test combined with an infra-red motion-tracking device. J Child Adolesc Psychopharmacol 21:433–444PubMedCrossRefGoogle Scholar
- Wilens TE, Robertson B, Sikirica V, Harper L, Young JL, Bloomfield R, Lyne A, Rynkowski G, Cutler AJ (2015) A randomized, placebo-controlled trial of guanfacine extended release in adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 54:916–925PubMedCrossRefGoogle Scholar